Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy

Inhibiting the programmed cell death ligand-1 (PD-L1)/programmed cell death receptor-1 (PD-1) signaling axis reinvigorates the antitumor immune response with remarkable clinical efficacy. Yet, low response rates limit the benefits of immunotherapy to a minority of patients. Recent studies have explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayala-Mar, Sergio, Donoso-Quezada, Javier, González-Valdez, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886511/
https://www.ncbi.nlm.nih.gov/pubmed/33628854
http://dx.doi.org/10.1155/2021/8839978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886511/
https://www.ncbi.nlm.nih.gov/pubmed/33628854
http://dx.doi.org/10.1155/2021/8839978

Ejemplares similares